MSP Recovery Claims, Series LLC et al v. Mallinckrodt Ard Inc., et al
Case Number:
3:20-cv-50056
Court:
Nature of Suit:
Judge:
Firms
- Arnold & Porter
- Bryan Cave
- Cooley LLP
- Milberg Coleman
- Pendley Baudin
- Quinn Emanuel
- Reno & Zahm
- Skadden Arps
- Williams McCarthy
- Wisner Baum
Companies
Sectors & Industries:
-
April 29, 2024
Judge Rejects Class Certification Of Seizure Drug Customers
An Illinois federal judge has rejected a class certification bid in a suit against drugmaker Mallinckrodt and prescription delivery platform Express Scripts, ruling that the plaintiffs were unable to meet their predominance burden as a class.
-
November 14, 2023
Express Scripts Wants Class Bid Cut In Acthar Case
Express Scripts and its subsidiaries asked an Illinois federal judge Monday not to certify a class of customers bringing antitrust allegations over sales of the anti-seizure drug Acthar, saying it doesn't make sense to proceed as a class action because so many potential members haven't been injured.
-
May 27, 2021
Judge Questions Bid To Move Acthar Cases To Delaware
A member of the Judicial Panel on Multidistrict Litigation on Thursday questioned Mallinckrodt ARD LLC's push to have a battery of antitrust cases over sales of the anti-seizure drug Acthar transferred to federal court in Delaware where the company is currently making its way through bankruptcy proceedings.
-
January 28, 2021
Mallinckrodt Seeks To Move Acthar Cases To Delaware
Mallinckrodt has urged federal courts around the country to transfer cases involving the drugmaker's hormone treatment Acthar that make claims for antitrust, racketeering and other violations to the Delaware court overseeing its bankruptcy.
-
March 23, 2020
Mallinckrodt Dodges MS Drug Monopoly Suit
An Illinois federal judge on Monday dismissed claims that drugmaker Mallinckrodt conspired with Express Scripts to artificially inflate the price of a drug used to treat infant seizures and multiple sclerosis, saying representatives of Medicare Advantage plans lacked standing to bring antitrust claims.